China Resources Pharmaceutical Group (HKSE:03320) Accounts Payable & Accrued Expense : HK$86,887 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Accounts Payable & Accrued Expense?

China Resources Pharmaceutical Group's quarterly accounts payable & accrued expense increased from Dec. 2022 (HK$87,613 Mil) to Jun. 2023 (HK$89,892 Mil) but then declined from Jun. 2023 (HK$89,892 Mil) to Dec. 2023 (HK$86,887 Mil).

China Resources Pharmaceutical Group's annual accounts payable & accrued expense declined from Dec. 2021 (HK$89,360 Mil) to Dec. 2022 (HK$87,613 Mil) and declined from Dec. 2022 (HK$87,613 Mil) to Dec. 2023 (HK$86,887 Mil).

China Resources Pharmaceutical Group Accounts Payable & Accrued Expense Historical Data

The historical data trend for China Resources Pharmaceutical Group's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Accounts Payable & Accrued Expense Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

72,665.95

76,752.20

89,360.13

87,613.20

86,887.16

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															89,360.13	83,190.14	87,613.20	89,892.31	86,887.16

China Resources Pharmaceutical Group Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

China Resources Pharmaceutical Group (HKSE:03320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Accounts Payable & Accrued Expense

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines